Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Amplification”

49 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 49 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)UnknownNCT05163249
What this trial is testing

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Guangdong Association of Clinical Trials 44
Not applicableLooking for participantsNCT05703516
What this trial is testing

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who this might be right for
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals 44
Testing effectiveness (Phase 2)Looking for participantsNCT05800340
What this trial is testing

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Who this might be right for
Non-Small Cell Lung CancerRET Driver MutationBRAF V600 Mutation+3 more
Guangdong Provincial People's Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06947291
What this trial is testing

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Who this might be right for
Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 350
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06885840
What this trial is testing

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 100
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Early research (Phase 1)Active Not RecruitingNCT02609776
What this trial is testing

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Janssen Research & Development, LLC 751
Testing effectiveness (Phase 2)Study completedNCT02449551
What this trial is testing

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)Study completedNCT02435121
What this trial is testing

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

Who this might be right for
Neoplasm Malignant
Sanofi 1
Testing effectiveness (Phase 2)Study completedNCT02447406
What this trial is testing

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 7
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Study completedNCT04084717
What this trial is testing

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Who this might be right for
Non-squamous Non-small-cell Lung CancerStage IV Non-small Cell Lung CancerROS1 Gene Rearrangement+2 more
University Health Network, Toronto 33
Testing effectiveness (Phase 2)Looking for participantsNCT06116682
What this trial is testing

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Who this might be right for
Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network 88
Testing effectiveness (Phase 2)UnknownNCT02946359
What this trial is testing

A+C in Metastatic Lung Adenocarcinoma Cancer

Who this might be right for
Lung Adenocarcinoma Metastatic
Chinese PLA General Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT07322783
What this trial is testing

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Who this might be right for
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT06908772
What this trial is testing

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Who this might be right for
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Shanghai JMT-Bio Inc. 390
Testing effectiveness (Phase 2)Looking for participantsNCT04270591
What this trial is testing

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Who this might be right for
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd. 183
Testing effectiveness (Phase 2)Ended earlyNCT02132598
What this trial is testing

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)Metastases to the Brain
Liza Villaruz, MD 5
Next Page